Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: CyclosporineBiological: FilgrastimDrug: FludarabineDrug: Mycophenolate MofetilDrug: Mycophenolate SodiumRadiation: Total-Body IrradiationDrug: TreosulfanProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: EchocardiographyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Positron Emission Tomography
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04195633
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT04149678
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- Radiation: Total-Body IrradiationDrug: ThiotepaDrug: FludarabineDrug: CyclophosphamideBiological: Peripheral Blood Stem CellDrug: TacrolimusBiological: Allogeneic CD34+-enriched and CD45RA-depleted PBSCsDrug: MethotrexateDrug: CyclosporineDrug: BusulfanDrug: SirolimusProcedure: Bone Marrow Aspiration and BiopsyProcedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: Biospecimen Collection
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT03970096
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 18
- Registration Number
- NCT03768609
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT03750383
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Conditions
- Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeMyelofibrosisRecurrent Hodgkin LymphomaTherapy-Related Acute Myeloid LeukemiaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHematopoietic and Lymphoid System NeoplasmAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRecurrent Non-Hodgkin Lymphoma
- Interventions
- Biological: Anti-Thymocyte GlobulinDrug: BusulfanDrug: CyclophosphamideDrug: CyclosporineDrug: Fludarabine PhosphateDrug: MethotrexateProcedure: Peripheral Blood Stem Cell TransplantationOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationDrug: TacrolimusRadiation: Total-Body Irradiation
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT03602898
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21
- Registration Number
- NCT03466567
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Huons Co., Ltd.
- Target Recruit Count
- 209
- Registration Number
- NCT03461575
- Locations
- 🇰🇷
Seoul ST.Mary's Hospital, Seoul, Korea, Republic of
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
- Conditions
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT03434730
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 54
- Registration Number
- NCT03419910
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.